Contact
searchSearch
HMP Global
Login

Brain Cancer Specialty Channel

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
Test Your Knowledge
Quiz: Is Large-Scale Outcome Data Currently Flawed in Brain Cancer Research?
01/12/2021
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the...
01/12/2021
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology

News

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology

Interactive Features

Test Your Knowledge
Quiz: Is Large-Scale Outcome Data Currently Flawed in Brain Cancer Research?
01/12/2021
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the...
01/12/2021
Oncology

Recent News

FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC
08/24/2020
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
In patients with SCLC,...
08/24/2020
Oncology
News
Pembrolizumab Safe, Active for Certain Patients With NSCLC and Brain Metastases
05/14/2020
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Pembrolizumab is safe and active...
05/14/2020
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology
News
Cranial Irradiation Reduces Long-term Risk for Brain Metastasis in NSCLC
04/02/2019
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Long-term results from a...
04/02/2019
Oncology
News
Neratinib–Capecitabine Combo Active Against Breast Cancer Brain Metastases
03/19/2019
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Supplementary study data support...
03/19/2019
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use